A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 755-760

  Tolcher, Anthony W ^a,d   O'Shaughnessy, Joyce A ^a   Weiss, Raymond B ^b   Zujewski, Joanne ^a   Myhand, Rick C ^b   Schneider, Erasmus ^a   Hakim, Fran ^a   Gress, Ronald ^a   Goldspiel, Barry ^c   Noone, Marianne H ^a   Brewster, Linda R ^b   Gossard, Michelle R ^c   Cowan, Ken H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CELL SELECTION; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS; TOPOTECAN;

EID: 0030957029     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
2. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
3. SK&F. Topotecan SmithKline & French 104864-A Investigator Brochure, March 1992.
4. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
5. Haas, N. B., LaCreta, F. P., Walczak, J., Hudes, G. R., Brennan, J., Ozols, R. F., and O'Dwyer, P. J. Phase I/pharmacokinetic trial of topotecan on a weekly 24-hour infusional schedule. Proc. Am. Assoc. Cancer Res., 33: 523, 1992.
6. Burris, H. A., Awada, A., Kuhn, J. G., Eckardt, J. R., Cobb, P. W., Rinaldi, D. A., Fields, S., Smith, L., and Von Hoff, D. D. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs, 5: 394-402, 1994.
7. Ross, W. E., Glaubiger, D. L., and Kohn, K. W. Protein-associated DNA breaks in cells treated with Adriamycin or ellipticine. Biochem. Biophys. Acta, 519: 23-30, 1978.
8. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Intercalative antitumor drugs intervene with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259: 9182-9187, 1984.
9. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991.
10. Lefevre, D., Riou, J-F., Ahomadegbe, J. C., Zhou, D., Benard, J., and Riou, G. Study of molecular markers of resistance to m-AMSA in a human breast cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione-S-transferase. Biochem. Pharmacol., 41: 1967-1979, 1991.
11. Oguro, M., Seki, Y., Okada, K., and Andoh, T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed. Pharmacother., 44: 209-216, 1990.
12. Anzai, H., Frost, P., and Abbruzzese, J. L. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc. Am. Assoc. Cancer Res., 33: 431, 1992.
13. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human xenografts in nude mice. Int. J. Cancer, 50: 760-766, 1992.
14. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in all killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
15. Holm, C., Coney, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
16. Burris, H. A., Awada, A., Kuhn, J. G., Eckardt, J. R., Cobb, P. W., Rinaldi, D. A., Fields, S., Smith, L., and Von Hoff, D. D. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs, 5: 394-402, 1994.
17. O'Shaughnessy, J. A., Denicoff, A. M., Venzon, D. J., Pierce, L. J., Frame, J. N., Bastian, A., Ghosh, B., Goldspiel, B., Miller, L., Dorr, F. A., Keegan, P., Ben-Baruch, N., Mrose, H., Noone, M., and Cowan, K. H. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and E. coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann. Oncol., 5: 709-716, 1994.
18. Eckardt, J. R., Burris, H. A., Von Hoff, D. D., Rodriguez, G. I., Fields, S. M., Rothenberg, M. L., Moore, T. D., Hodges, S., Weiss, G. R., Cobb, P., Rinaldi, D., Kuhn, J. G., Ford, J., and Ganapathi, R. Measurement of tumour topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc. Am. Soc. Clin. Oncol., 13: 141, 1994.
19. Lilenbaum, R. C., Ratain, M. J., Miller, A. A., Hargis, J. B., Hollis, D. R., Rosner, G. L., O'Brien, S. M., Brewster, L., Green, M. R., and Schilsky, R. L. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J. Clin. Oncol., 13: 2230-2237, 1995.
20. Rowinsky, E. K., Kaufmann, S. H., Baker, S. D., Grochow, L. B., Chen, T. L., Peereboom. D., Bowling, M. K., Sartorius, S. E., Ettinger, D. S., Forastiere, A. A., and Donehower, R. C. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol., 14: 3074-3084, 1996.
21. Miller, A. A., Hargis, J. B., Lilenbaum. R., Fields, S. Z., Rosner, G. L., and Schilsky, R. L. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a Cancer and Leukemia Group B study. J. Clin. Oncol., 12: 2743-2750, 1994.
22. Kantarjian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M. B., Plunkett, W., Keating, M. J., and Estey, E. H. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 5: 1146-1151, 1993.
23. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y. C., Grochow, L. B., and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 194.